New therapeutic strategy for metastatic prostate cancer patients resistant to standard treatment

A group of researchers from the Badalona Utilized Analysis Group in Oncology (B·ARGO) and the Urologic Tumors Unit of the Institut Català d’Oncologia (ICO) and the Germans Trias i Pujol Analysis Institute (IGTP) have discovered a brand new therapeutic technique for sufferers with a selected subtype of metastatic prostate most cancers resistant to straightforward chemotherapy therapy with docetaxel.

On this research, revealed within the journal Frontiers in Pharmacologythey suggest a brand new therapy based mostly on a mixture of kinase inhibitors in sufferers who inevitably cease responding to docetaxel.

The group discovered that resistance to this drug is related to the hyperactivation of the mobile pathways PI3K/AKT and MEK/ERK and have explored the potential for inhibiting these pathways as a brand new therapeutic technique in sufferers who keep the perform of PTEN, a destructive regulatory protein of the PI3K/AKT pathway.

The outcomes of the research have been passable and, because of this, the group desires to conduct a medical trial to evaluate the security and efficacy of this mix in sufferers with prostate most cancers immune to docetaxel.

Vicenç Ruiz de Porras and Adrià Bernat-Peguera, ICO-IGTP researchers and co-first authors of the research, state that the outcomes of this research “open the door to a brand new therapeutic technique for these sufferers with PTEN wild-type tumors, who’ve progressed to docetaxel and in whom, in contrast to PTEN null patientsthe efficacy of AKT inhibitors in monotherapy has not been demonstrated.”

Offered by
Germans Trias i Pujol Analysis Institute